Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management

S Shimony, M Stahl, RM Stone - American Journal of …, 2023 - Wiley Online Library
Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity

F Veglia, E Sanseviero, DI Gabrilovich - Nature Reviews Immunology, 2021 - nature.com
Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and
monocytes with potent immunosuppressive activity. They are implicated in the regulation of …

Towards precision medicine for AML

H Döhner, AH Wei, B Löwenberg - Nature reviews Clinical oncology, 2021 - nature.com
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

Current status and future perspectives in targeted therapy of NPM1-mutated AML

R Ranieri, G Pianigiani, S Sciabolacci, VM Perriello… - Leukemia, 2022 - nature.com
Abstract Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is
predominantly located in the nucleolus and exerts multiple functions, including regulation of …

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

N Duployez, L Largeaud, M Duchmann… - Blood, The Journal …, 2022 - ashpublications.org
DDX41 germline mutations (DDX41MutGL) are the most common genetic predisposition to
myelodysplastic syndrome and acute myeloid leukemia (AML). Recent reports suggest that …

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label …

H Döhner, D Weber, J Krzykalla, W Fiedler… - The Lancet …, 2023 - thelancet.com
Background Acute myeloid leukaemia with mutated NPM1 is associated with high CD33
expression and intermediate-risk cytogenetics. The aim of this study was to evaluate …

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

L Tang, Z Huang, H Mei, Y Hu - Signal Transduction and Targeted …, 2023 - nature.com
The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

How I treat pediatric acute myeloid leukemia

JE Rubnitz, GJL Kaspers - Blood, The Journal of the American …, 2021 - ashpublications.org
Abstract Treatment outcomes for pediatric patients with acute myeloid leukemia (AML) have
continued to lag behind outcomes reported for children with acute lymphoblastic leukemia …

How I diagnose and treat NPM1-mutated AML

B Falini, L Brunetti, MP Martelli - Blood, The Journal of the …, 2021 - ashpublications.org
Mutations of the nucleophosmin (NPM1) gene, encoding for a nucleolar multifunctional
protein, occur in approximately one-third of adult acute myeloid leukemia (AML). NPM1 …

Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy

K Sasaki, T Kadia, K Begna… - American journal of …, 2022 - Wiley Online Library
The progress with intensive chemotherapy and supportive care measures has improved
survival in patients with newly diagnosed acute myeloid leukemia (AML). Given the recent …